MERIT ONCOLOGY EXPANDS TO EUROPE, MIDDLE EAST & AFRICA (EMEA) TO TREAT MORE PATIENTS GLOBALLY
Merit Oncology’s newest technology is SCOUT® Radar Localization, an advanced wire-free radar localization system designed to improve the precision and predictability of marking tumors, biopsy sites, and lymph nodes prior to neoadjuvant therapy and surgery. SCOUT Radar Localization is the wire-free platform that exclusively spans the care continuum from biopsy to surgery. Launched in the United States in 2015, more than 930 consoles have been placed, SCOUT has been used in over 200,000 procedures and is supported by over 60 clinical publications.
Wire-free localization is quickly becoming the standard of care for achieving optimal clinical results while providing patients a better overall experience. Since its approval in Europe in March, 2020, SCOUT has been referenced in two European publications.